Compare
Zura Bio Ltd vs Lineage Cell Therapeutics, Inc. vs Artiva Biotherapeutics, Inc. vs Surrozen, Inc.
| Latest fiscal year | Zura Bio Ltd ZURA | Lineage Cell Therapeutics, Inc. LCTX | Artiva Biotherapeutics, Inc. ARTV | Surrozen, Inc. SRZN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $14.56M | $0 | $3.48M |
| Revenue growth (YoY) | n/a | +53.2% | -100.0% | -67.4% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -251.6% | n/a | n/m |
| Net margin | n/a | -436.5% | n/a | n/m |
| Net income | -$68.65M | -$63.53M | -$83.86M | -$242.03M |
| EPS (Diluted) | -$1.06 | -$0.28 | -$3.43 | -$32.37 |
| Operating cash flow | -$64.81M | -$18.92M | -$76.75M | -$30.24M |
| Free cash flow | -$64.93M | -$19.44M | -$79.34M | -$30.37M |
| Cash & equivalents | $109.41M | $40.79M | $26.70M | $89.25M |
| Total assets | $113.95M | $112.58M | $130.94M | $98.73M |
| Total liabilities | $12.41M | $69.24M | $20.97M | $286.49M |
| Shareholders' equity | $101.54M | $43.35M | $109.97M | -$187.76M |
| Return on year-end equity | -67.6% | -146.6% | -76.3% | n/a |
| Shares outstanding | 73.68M | 243.12M | n/a | 9.78M |
Revenue, most recent five fiscal years
| Fiscal year | Zura Bio Ltd | Lineage Cell Therapeutics, Inc. | Artiva Biotherapeutics, Inc. | Surrozen, Inc. |
|---|---|---|---|---|
| Latest | n/a | $14.56M Ended 2025-12-31 | $0 Ended 2025-12-31 | $3.48M Ended 2025-12-31 |
| 1 year earlier | n/a | $9.50M Ended 2024-12-31 | $251.0K Ended 2024-12-31 | $10.65M Ended 2024-12-31 |
| 2 years earlier | n/a | $8.95M Ended 2023-12-31 | $33.49M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $14.70M Ended 2022-12-31 | n/a | $12.50M Ended 2022-12-31 |
| 4 years earlier | n/a | $4.34M Ended 2021-12-31 | n/a | $0 Ended 2021-12-31 |